This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Investigation for parvovirus B19 of a pregnant woman with significant exposure to rash illness

Authoring team

Investigation for parvovirus B19 of a pregnant woman with significant exposure to rash illness

The risk of fetal loss appears to be similar in both asymptomatic patients and in women with the parvovirus B19 infection rash (1)

If a pregnant woman has had significant exposure (being in the same room for over 15 minutes, or face-to-face contact) with a person suffering from a non vesicular rash, she should be examined for both asymptomatic rubella and asymptomatic parvovirus B19 infection (4)

  • delaying of the examination (to find out if symptomatic infection occurs) should not be done
  • serum should be tested for parvovirus B19 specific IgM as well as for IgG o if IgG positive and IgM negative - woman should be reassured that she has had a previous parvovirus B19 infection but not recently
    • if IgG negative and IgM positive - further test should be done immediately
    • if both IgG and IgM are negative - another test should be done one month after last contact,
    • if after one month still IgG and IgM are negative the women should be informed that there is no evidence of recent infection but is susceptible (2)

Reference:


Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.